Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Ludotadipep in Metastatic Castration-resistant Prostate Cancer
NCT07853209Phase 3Recruiting
- Sponsor
- FutureChem Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 3 trial of Ludotadipep in prostate cancer (PCa), sponsored by FutureChem Co., Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
Ludotadipep
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07853209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07853209.